| PCSK9-binding macrocyclic peptide pharmacophoreAbstract pharmacophorepcsk9-macrocycle-corePage | Scaffold | CC(C)C[C@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C… | — | — | PCSK9 · macrocycle · core · LDL-C · Shared pharmacophore / core scaffold. Anchor for the PCSK9 inhibitor chemical & modality s… |
| Alirocumab (Praluent)Verified drugalirocumabPage | Drug | CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)N)C(=… | PCSK9-binding macrocyclic peptide pharmacophore | 17%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | approved · PCSK9 · mAb · injectable · Approved therapeutic. Alirocumab (Praluent) in this family map. · CHEMBL1743034 |
| Enlicitide (Lipfendra)Verified drugenlicitidePage | Drug | CC(C)C[C@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O… | PCSK9-binding macrocyclic peptide pharmacophore | 66%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | approved · PCSK9 · oral · Lipfendra · MK-0616 · First FDA-approved once-daily oral PCSK9 inhibitor (macrocyclic peptide); adjunct to diet/… |
| Evolocumab (Repatha)Verified drugevolocumabPage | Drug | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)N)C(=O)N… | PCSK9-binding macrocyclic peptide pharmacophore | 22%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | approved · PCSK9 · mAb · injectable · Anti-PCSK9 monoclonal antibody — Q2W/QM SC injection class peer to oral enlicitide. · CHEMBL2107838 |
| Inclisiran (Leqvio)Verified druginclisiranPage | Drug | Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)O)[C@@… | PCSK9-binding macrocyclic peptide pharmacophore | 9%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | approved · PCSK9 · siRNA · injectable · PCSK9-targeting siRNA — twice-yearly dosing after loading; modality contrast to oral pepti… · CID 133086079 |
| Lerodalcibep (LIB003)Known compoundlerodalcibepPage | Drug | CC(C)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C… | PCSK9-binding macrocyclic peptide pharmacophore | 25%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | clinical · PCSK9 · adnectin · Clinical-stage candidate. Lerodalcibep (LIB003) in this family map. |
| MK-0616 (enlicitide development code)Exploratory analogmk-0616Page | Derivative | CC(C)C[C@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O… | Enlicitide (Lipfendra) | 66%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | clinical · PCSK9 · oral · Clinical-stage candidate. Derived analog of parent node in PCSK9 inhibitor chemical & moda… |
| Oral PCSK9i amide SAR analogExploratory analog (rule-generated)pcsk9-oral-sar-amidePage | Derivative | CC(C)C[C@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O… | Enlicitide (Lipfendra) | 65%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | SAR · oral · PCSK9 · SAR exploration node. Derived analog of parent node in PCSK9 inhibitor chemical & modality… |
| Oral PCSK9i fluoro-macrocycle analogExploratory analog (rule-generated)pcsk9-oral-sar-fluoroPage | Derivative | CC(C)C[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O… | Oral PCSK9i amide SAR analog | 65%iStructural similarity calculated using Morgan fingerprint (RDKit circular fingerprint, radius 2, 2048 bits) with Tanimoto similarity. Structural similarity does not predict biological equivalence, potency, safety, or clinical efficacy. | SAR · F-scan · PCSK9 · SAR exploration node. Derived analog of parent node in PCSK9 inhibitor chemical & modality… |